J-Pharma

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

October 30, 2026

To Whom It May Concern

Company Name:	J-Pharma Co., Ltd.
Name of Representative:	President and CEO Masuhiro Yoshitake
Securities Code:	520A Tokyo Stock Exchange Growth Market
Contact:	Director and CFO Yutaka Fujimoto
Telephone:	+81-3-6432-4270

Notice of Grant approval and Commencement of the Grant-Funded Project under AMED's GRiT Program

— Grant approved for the maximum amount of JPY 1.5 billion —

J-Pharma Co., Ltd. (Head Office: Minato-ku, Tokyo; President and CEO: Masuhiro Yoshitake; hereinafter the "Company") today announced that it has received approval for a JPY 1.5 billion grant under the FY2026 Program for Promoting the Development of Innovative Medical Technologies (Industry–Government–Academia Collaboration), Global Type (Global Research and Development Support Program for the Treatment of Intractable and Rare Diseases; the "GRiT Program"), administered by the Japan Agency for Medical Research and Development (AMED). The approved grant matches the full amount requested and the maximum available under the program. The Company has commenced the grant-funded project.

■ Overview

Following selection for the program, the Company proceeded with the grant application process. The Company has now received approval for a grant of JPY 1.5 billion, the maximum amount available and the full amount requested, and commenced the grant-funded project on October 29, 2026.

The Company will use the support provided under this program to steadily advance Part A of the global Phase III clinical trial, Beacon-BTC.

■ Grant-Funded Project Period and Approved Grant Amount

Project period: October 29, 2026 – December 31, 2028

Approved grant amount: JPY 1.5 billion

■ Impact on Financial Results

The Company is currently assessing the impact of this grant on its financial results and will promptly announce any information that requires disclosure.

For an overview of the project and the significance of its selection, please refer to the following news release.

"J-Pharma Selected for Funding under AMED's Global Research and Development Support Project for the Treatment of Intractable/Rare Diseases"(October 5, 2026)

https://www.j-pharma.com/en/news/3718/

.

About *Nanvuranlat*

Nanvuranlat (development code: JPH203) is a novel LAT1-selective inhibitor originally discovered by J-Pharma and is the first small-molecule compound of its kind to be clinically developed worldwide. LAT1 (L-type amino acid transporter 1) is one of the transporters involved in cellular amino acid uptake and is known to be highly expressed in many cancer cells. If approved, nanvuranlat could become a first-in-class drug with a new mechanism of action for its target disease.

Since 2015, J-Pharma has conducted Phase I clinical studies in multiple solid tumors and identified its potential for the treatment of advanced biliary tract cancer. A Phase II trial in advanced biliary tract cancer, initiated in 2018, demonstrated a significant improvement in progression-free survival (PFS) compared with placebo and a favorable safety profile.*

Nanvuranlat was designated as an orphan drug by the U.S. Food and Drug Administration (FDA) in April 2022. Furthermore, on September 25, 2024, the Investigational New Drug (IND) application for clinical studies in cancer patients was accepted by the FDA. In addition, in May 2025, J-Pharma confirmed that the Chemistry, Manufacturing, and Controls (CMC) at the commercial manufacturing scale meet the quality standards required by the FDA. Based on these developments, the Company initiated a global Phase III clinical trial in December 2025.

* Publication on the results of the Japan Phase II clinical study of *Nanvuranlat*:
Furuse et al. A Phase II Placebo-Controlled Study of the Effect and Safety of *Nanvuranlat* in Patients with Advanced Biliary Tract Cancers Previously Treated by Systemic Chemotherapy. Clin Cancer Res. 2024;30(18):3990-3995. https://doi.org/10.1158/1078-0432.CCR-24-0461

About J-Pharma Co., Ltd.

J-Pharma Co., Ltd. aims to pursue new possibilities for SLC transporters and contribute to the hope and health of people worldwide through the development of innovative new drugs that address unmet medical needs. Under this mission, the Company has focused on LAT1 (L-type amino acid transporter 1), one of the SLC transporters discovered by the Company's founder, and is advancing the development of LAT1 inhibitors to address the needs of patients with cancer and autoimmune diseases, where existing drugs are insufficient.
For more information, please visit: https://www.j-pharma.com/en/

Inquiries:

J-Pharma Co., Ltd.
Planning Department
TEL: +81-3-6432-4270
https://www.j-pharma.com/en/contact